IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients.
暂无分享,去创建一个
[1] T. Nomura,et al. Control of Regulatory T Cell Development by the Transcription Factor Foxp3 , 2002 .
[2] M. Rep,et al. Phenotypic and Functional Separation of Memory and Effector Human CD8+ T Cells , 1997, The Journal of experimental medicine.
[3] N. Restifo,et al. CD4+CD25+ T regulatory cells, immunotherapy of cancer, and interleukin-2. , 2005, Journal of immunotherapy.
[4] F. Sallusto,et al. Coexpression of CD25 and CD27 identifies FoxP3+ regulatory T cells in inflamed synovia , 2005, The Journal of experimental medicine.
[5] G. Schuler,et al. Ex Vivo Isolation and Characterization of Cd4+Cd25+ T Cells with Regulatory Properties from Human Blood , 2001, The Journal of experimental medicine.
[6] C. Baecher-Allan,et al. Human CD4+CD25+ regulatory T cells. , 2004, Seminars in immunology.
[7] T. Malek,et al. The main function of IL‐2 is to promote the development of T regulatory cells , 2003, Journal of leukocyte biology.
[8] T. Malek,et al. Tolerance, not immunity, crucially depends on IL-2 , 2004, Nature Reviews Immunology.
[9] A. Enk,et al. Identification and Functional Characterization of Human Cd4+Cd25+ T Cells with Regulatory Properties Isolated from Peripheral Blood , 2001, The Journal of experimental medicine.
[10] Ethan M. Shevach,et al. Cutting Edge: IL-2 Is Critically Required for the In Vitro Activation of CD4+CD25+ T Cell Suppressor Function , 2004, The Journal of Immunology.
[11] S. Rosenberg,et al. CD8+ T Cell Immunity Against a Tumor/Self-Antigen Is Augmented by CD4+ T Helper Cells and Hindered by Naturally Occurring T Regulatory Cells , 2005, The Journal of Immunology.
[12] R. Gallo,et al. Selective in vitro growth of T lymphocytes from normal human bone marrows. , 1976, Science.
[13] J. Bluestone,et al. FOCIS abstract supplement , 2005, Clinical Immunology.
[14] Shimon Sakaguchi,et al. Homeostatic maintenance of natural Foxp3 + CD25+ CD4+ regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization , 2005, The Journal of experimental medicine.
[15] J. Shimizu,et al. Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. , 1999, Journal of immunology.
[16] T. Waldmann,et al. Interleukin 2 (IL-2) augments transcription of the IL-2 receptor gene. , 1985, Proceedings of the National Academy of Sciences of the United States of America.
[17] G. Freeman,et al. CD4+CD25high Regulatory Cells in Human Peripheral Blood1 , 2001, The Journal of Immunology.
[18] J. Aerts,et al. Selection of appropriate control genes to assess expression of tumor antigens using real-time RT-PCR. , 2004, BioTechniques.
[19] A. Rudensky,et al. Regulatory T cell lineage specification by the forkhead transcription factor foxp3. , 2005, Immunity.
[20] T. Nomura,et al. Crucial role of FOXP3 in the development and function of human CD25+CD4+ regulatory T cells. , 2004, International immunology.
[21] S. Rosenberg,et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. , 1994, JAMA.
[22] T. Mak,et al. Immunologic Self-Tolerance Maintained by Cd25+Cd4+Regulatory T Cells Constitutively Expressing Cytotoxic T Lymphocyte–Associated Antigen 4 , 2000, The Journal of experimental medicine.
[23] A. Rudensky,et al. A well adapted regulatory contrivance: regulatory T cell development and the forkhead family transcription factor Foxp3 , 2005, Nature Immunology.
[24] J. Bluestone. Regulatory T-cell therapy: is it ready for the clinic? , 2005, Nature Reviews Immunology.
[25] F. Miedema,et al. The CD27− subset of peripheral blood memory CD4+ lymphocytes contains functionally differentiated T lymphocytes that develop by persistent antigenic stimulation in vivo , 1992, European journal of immunology.
[26] J. Lafaille,et al. Interleukin 2 Signaling Is Required for CD4+ Regulatory T Cell Function , 2002, The Journal of experimental medicine.